ViroGates (VIRO) Stock Overview
An in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VIRO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ViroGates A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 12.10 |
| 52 Week High | DKK 31.00 |
| 52 Week Low | DKK 5.98 |
| Beta | 0.96 |
| 1 Month Change | -4.72% |
| 3 Month Change | 21.00% |
| 1 Year Change | -10.37% |
| 3 Year Change | -70.49% |
| 5 Year Change | -80.00% |
| Change since IPO | -85.85% |
Recent News & Updates
Recent updates
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans
Mar 06
We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
Nov 21Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?
Jun 14We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate
Sep 19We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Apr 14We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Dec 30
Shareholder Returns
| VIRO | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | -9.4% | 0.2% | -2.8% |
| 1Y | -10.4% | -29.1% | -37.4% |
Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned -29.1% over the past year.
Return vs Market: VIRO exceeded the Danish Market which returned -37.4% over the past year.
Price Volatility
| VIRO volatility | |
|---|---|
| VIRO Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 10.0% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: VIRO's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: VIRO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; and suPARnostic Quick Triage kit for use in the point of care situation for early warning and patient triaging that allows clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression, and outcome.
ViroGates A/S Fundamentals Summary
| VIRO fundamental statistics | |
|---|---|
| Market cap | DKK 93.59m |
| Earnings (TTM) | -DKK 12.39m |
| Revenue (TTM) | DKK 8.07m |
Is VIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRO income statement (TTM) | |
|---|---|
| Revenue | DKK 8.07m |
| Cost of Revenue | DKK 2.66m |
| Gross Profit | DKK 5.41m |
| Other Expenses | DKK 17.80m |
| Earnings | -DKK 12.39m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Nov 10, 2025
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 67.09% |
| Net Profit Margin | -153.51% |
| Debt/Equity Ratio | 168.6% |
How did VIRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/09 10:31 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ViroGates A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.